Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
Pérez-Guijarro E, Yang HH, Araya RE, El Meskini R, Michael HT, Vodnala SK, Marie KL, Smith C, Chin S, Lam KC, Thorkelsson A, Iacovelli AJ, Kulaga A, Fon A, Michalowski AM, Hugo W, Lo RS, Restifo NP, Sharan SK, Van Dyke T, Goldszmid RS, Weaver Ohler Z, Lee MP, Day CP, Merlino G. Pérez-Guijarro E, et al. Among authors: van dyke t. Nat Med. 2020 May;26(5):781-791. doi: 10.1038/s41591-020-0818-3. Epub 2020 Apr 13. Nat Med. 2020. PMID: 32284588 Free PMC article.
Meeting report: The future of preclinical mouse models in melanoma treatment is now.
Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M. Merlino G, et al. Among authors: van dyke t. Pigment Cell Melanoma Res. 2013 Jul;26(4):E8-E14. doi: 10.1111/pcmr.12099. Epub 2013 Apr 8. Pigment Cell Melanoma Res. 2013. PMID: 23531109 Free PMC article. No abstract available.
"Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts.
Day CP, Carter J, Weaver Ohler Z, Bonomi C, El Meskini R, Martin P, Graff-Cherry C, Feigenbaum L, Tüting T, Van Dyke T, Hollingshead M, Merlino G. Day CP, et al. Among authors: van dyke t. PLoS One. 2014 Nov 4;9(11):e109956. doi: 10.1371/journal.pone.0109956. eCollection 2014. PLoS One. 2014. PMID: 25369133 Free PMC article.
Concepts in Cancer Modeling: A Brief History.
Thomas RM, Van Dyke T, Merlino G, Day CP. Thomas RM, et al. Among authors: van dyke t. Cancer Res. 2016 Oct 15;76(20):5921-5925. doi: 10.1158/0008-5472.CAN-16-1293. Epub 2016 Sep 30. Cancer Res. 2016. PMID: 27694601 Free PMC article. Review.
Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
Pérez-Guijarro E, Yang HH, Araya RE, El Meskini R, Michael HT, Vodnala SK, Marie KL, Smith C, Chin S, Lam KC, Thorkelsson A, Iacovelli AJ, Kulaga A, Fon A, Michalowski AM, Hugo W, Lo RS, Restifo NP, Sharan SK, Van Dyke T, Goldszmid RS, Weaver Ohler Z, Lee MP, Day CP, Merlino G. Pérez-Guijarro E, et al. Among authors: van dyke t. Nat Med. 2021 Feb;27(2):355. doi: 10.1038/s41591-021-01252-6. Nat Med. 2021. PMID: 33514948 No abstract available.
Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.
El Meskini R, Atkinson D, Kulaga A, Abdelmaksoud A, Gumprecht M, Pate N, Hayes S, Oberst M, Kaplan IM, Raber P, Van Dyke T, Sharan SK, Hollingsworth R, Day CP, Merlino G, Weaver Ohler Z. El Meskini R, et al. Among authors: van dyke t. Mol Cancer Res. 2021 Aug;19(8):1422-1436. doi: 10.1158/1541-7786.MCR-20-0881. Epub 2021 Apr 22. Mol Cancer Res. 2021. PMID: 33888600 Free PMC article.
β-catenin in metastatic melanoma--the smoking gun reloaded.
Van Dyke T, Merlino G. Van Dyke T, et al. Pigment Cell Melanoma Res. 2012 Mar;25(2):125-6. doi: 10.1111/j.1755-148X.2011.00964.x. Epub 2012 Jan 12. Pigment Cell Melanoma Res. 2012. PMID: 22409365 Free PMC article. No abstract available.
544 results